Cisplatin has saved countless lives by attacking rapidly dividing cancer cells, but the same chemical weapon can also injure the delicate sensory machinery of the inner ear. A study published in Cell Death Discovery now reports that short-chain fatty acids, metabolites produced by intestinal microbes, can significantly reduce cisplatin-induced damage to auditory sensory cells and hearing. The work identifies the DNA-repair protein MUTYH as a critical molecular link between these microbial metabolites and protection from ototoxicity, raising the possibility that the gut–ear axis could become an important target in efforts to preserve hearing during cancer treatment.
Cisplatin is a platinum-based chemotherapy drug used against a wide range of malignancies, including cancers of the head and neck, lung, ovary, bladder and testis. Its anticancer activity depends largely on its ability to bind DNA and create platinum–DNA adducts. These lesions distort the DNA double helix and interfere with replication and transcription, ultimately triggering cell death in vulnerable tumor cells. However, cisplatin can also reach the cochlea, the spiral-shaped organ responsible for hearing, where it may accumulate and generate oxidative stress. The resulting injury frequently affects cochlear hair cells, particularly the outer hair cells that amplify sound vibrations and convert them into electrical signals for the brain.
Unlike many tissues, mature mammalian auditory hair cells have little capacity for regeneration. Once these cells are destroyed, the resulting hearing loss is often permanent. Cisplatin-associated ototoxicity can begin with ringing in the ears, difficulty understanding high-frequency sounds and abnormal sensitivity to everyday noise before progressing to broader auditory impairment. The severity of the damage varies among patients and can depend on factors such as cumulative dose, age, genetic background and other medications. Because cisplatin remains highly effective against aggressive cancers, doctors face a difficult balance: protecting the ear without weakening the drug’s ability to destroy malignant cells.
The new research focuses on short-chain fatty acids, or SCFAs, including acetate, propionate and butyrate. These molecules are generated when beneficial intestinal bacteria ferment dietary fiber that the human digestive system cannot fully break down. SCFAs are best known for supporting intestinal health, but they also act as signaling molecules throughout the body. They can influence immune activity, cellular metabolism, mitochondrial function and gene regulation. Some SCFAs interact with cell-surface receptors such as G-protein-coupled receptors, while others enter cells and inhibit enzymes known as histone deacetylases. Through these mechanisms, SCFAs can alter the accessibility of DNA and change the expression of genes involved in inflammation, stress responses and tissue maintenance.
According to the study, SCFAs significantly alleviated the structural and functional damage caused by cisplatin in auditory sensory cells. The investigators linked this protective effect to the preservation of MUTYH expression. MUTYH, whose name derives from “mutY homolog,” is a DNA glycosylase involved in base-excision repair, one of the cell’s major systems for correcting small but potentially dangerous DNA lesions. A central target of MUTYH is an adenine mistakenly paired with 8-oxoguanine, a modified DNA base produced when reactive oxygen species attack guanine. If this mismatch is not corrected, it can generate permanent genetic mutations during DNA replication.
The connection is particularly relevant to cisplatin-induced cochlear injury because oxidative stress is considered a major driver of hair-cell degeneration. Cisplatin can disturb mitochondrial activity, increase the production of reactive oxygen species and activate cellular pathways associated with inflammation and programmed cell death. Oxidized DNA bases may accumulate as a consequence. By maintaining MUTYH expression, SCFAs may help sensory cells recognize and remove specific oxidative DNA lesions before they become more serious forms of genomic damage. The findings therefore suggest that the protective action of SCFAs is not limited to general antioxidant activity; it may also involve preserving the machinery that repairs DNA after oxidative attack.
The study’s implications extend beyond a single protein or one chemotherapy complication. It presents the gut microbiome as a possible regulator of vulnerability in tissues far from the intestine. The bacteria living in the digestive tract differ substantially between individuals, and so does their production of SCFAs. Diet, antibiotic exposure, illness, age and cancer treatment can all reshape microbial communities and alter the amount and composition of metabolites entering circulation. If SCFA availability influences MUTYH expression in the cochlea, differences in the gut microbiome could help explain why some patients experience severe cisplatin-related hearing loss while others retain better auditory function after similar treatment.
At the same time, the findings should not yet be interpreted as proof that eating more fiber, taking a probiotic or using an SCFA supplement can prevent hearing loss in people receiving cisplatin. The study establishes a promising biological relationship, but laboratory protection must be translated carefully into safe clinical strategies. The dose, timing and route of SCFA delivery will matter, as will the question of whether a treatment can protect sensory cells without reducing cisplatin’s anticancer effect. A compound that broadly changes gene expression or immune signaling could have unintended consequences in patients whose tumors and normal tissues are already under intense physiological stress.
Future work will need to determine precisely how SCFAs preserve MUTYH expression and whether that effect depends on a particular receptor, epigenetic pathway or metabolic state. Researchers will also need to test whether MUTYH is required for protection, rather than simply associated with it, by increasing or disabling the protein in controlled experimental systems. Studies in animal models and, eventually, carefully designed clinical trials could reveal whether SCFA-based interventions reduce measurable hearing loss, tinnitus and cochlear injury during chemotherapy. For now, the report offers a striking mechanistic insight: metabolites created by gut bacteria may help defend the inner ear against one of oncology’s most damaging side effects by sustaining a fundamental DNA-repair pathway. That possibility places MUTYH at the center of an emerging strategy to make lifesaving cancer treatment less costly for the senses.
Subject of Research: Protection against cisplatin-induced sensory cell damage and hearing loss through short-chain fatty acids and MUTYH expression.
Article Title: Short-chain fatty acids significantly alleviate cisplatin induced sensory cell damage and hearing loss by maintaining the expression of MUTYH.
Article References: Zhang, ZX., Zhu, YQ., Yan, FX. et al. Short-chain fatty acids significantly alleviate cisplatin induced sensory cell damage and hearing loss by maintaining the expression of MUTYH. Cell Death Discovery. (2026). https://doi.org/10.1038/s41420-026-03283-9
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41420-026-03283-9
Keywords: cisplatin, hearing loss, ototoxicity, short-chain fatty acids, MUTYH, DNA repair, oxidative stress, cochlear hair cells, gut–ear axis, cancer treatment.
